News
JMP Securities Reiterates Market Outperform on Ocular Therapeutix, Maintains $24 Price Target
13 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Decoding 6 Analyst Evaluations For Ocular Therapeutix
13 Mar 24
Analyst Ratings
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $15
13 Mar 24
News, Price Target, Analyst Ratings
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
12 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
These Analysts Boost Their Forecasts On Ocular Therapeutix After Q4 Results
12 Mar 24
Earnings, News, Price Target, Small Cap, Markets, Analyst Ratings, Trading Ideas
TD Cowen Maintains Market Perform on Ocular Therapeutix, Raises Price Target to $11
12 Mar 24
News, Price Target, Analyst Ratings
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $24
12 Mar 24
News, Price Target, Analyst Ratings
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
12 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
12 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Monday's After-Market Session
11 Mar 24
Movers
Ocular Therapeutix: Q4 Earnings Insights
11 Mar 24
Earnings
Ocular Therapeutix Q4 2023 GAAP EPS $(0.35) Misses $(0.30) Estimate, Sales $14.802M Miss $15.707M Estimate
11 Mar 24
Earnings, Earnings Misses, News
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
11 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Earnings Scheduled For March 11, 2024
11 Mar 24
Earnings
Earnings Outlook For Ocular Therapeutix
8 Mar 24
Earnings
$7M Bet On Ocular Therapeutix? Check Out These 3 Stocks Insiders Are Buying
28 Feb 24
Long Ideas, News, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
Piper Sandler Maintains Overweight Rating for Ocular Therapeutix: Here's What You Need To Know
26 Feb 24
Analyst Ratings
Piper Sandler Maintains Overweight on Ocular Therapeutix, Raises Price Target to $15
26 Feb 24
News, Price Target, Analyst Ratings
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
22 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Thursday's Intraday Session
22 Feb 24
Movers
Press releases
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
26 Mar 24
News, Press Releases
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
5 Mar 24
Press Releases
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
22 Feb 24
News, Health Care, Management, Press Releases
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
22 Feb 24
News, Dividends, Press Releases
Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
22 Feb 24
News, Management, Press Releases
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
19 Feb 24
Press Releases
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
15 Feb 24
News, Management, Press Releases
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
13 Feb 24
Health Care, Press Releases
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
12 Feb 24
Opinion, Press Releases
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
25 Jan 24
Press Releases, General